3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
4
Stomach Neoplasms
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Leukemia, Biphenotypic, Acute
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Burkitt Lymphoma
1
Biliary Tract Neoplasms
1
Interventions
Gemcitabine
23
Cisplatin
22
durvalumab
13
pembrolizumab
8
Oxaliplatin
7
Capecitabine
7
Fluorouracil
6
Leucovorin
5
Bevacizumab
5
lenvatinib
4
Albumin-Bound Paclitaxel
4
130-nm albumin-bound paclitaxel
4
Nivolumab
3
Liquid Biopsy
3
Injections
3
Folfox protocol
3
zanidatamab
2
trifluridine tipiracil drug combination
2
tremelimumab
2
tislelizumab
2
ivosidenib
2
futibatinib
2
apatinib
2
Trastuzumab
2
Taxes
2
Irinotecan
2
Immune Checkpoint Inhibitors
2
Drug Therapy
2
Carboplatin
2
Blood Specimen Collection
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Biliary Tract Neoplasms
×
Levoleucovorin
×
Clear all
NCT06428409
2026-01-22
MK-9999-02A
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
220 enrolled